RIMOXCLAMIN's Therapeutic Impact in a Larger Brazilian Hansen's Disease Population
Abstract
BACKGROUND: RIMOXCLAMIN, a new antibiotic regimen for Hansen's disease (HD), combines rifampicin, moxifloxacin, clarithromycin, and minocycline; the WHO-MDT combines rifampicin, dapsone, and clofazimine. To overcome limitations of WHO-MDT, we evaluated both regimens in a 2-arm cohort of multibacillary patients.
METHODS: Two-arm observational cohort included 162 newly diagnosed multibacillary cases (103 RIMOXCLAMIN and 59 WHO-MDT) evaluated between 2015 and 2025. Patients were assessed at least quarterly (baseline and months 3, 6, and 12) for neurological and cutaneous findings, adverse events, tactile sensitivity, and physical disability grade (PDG).
RESULTS: Neurological symptoms were frequent regardless of lesion count (≤5 vs > 5; P > .05). RIMOXCLAMIN demonstrated a greater reduction in nerve thickening than WHO-MDT (P < .0001) and increased PDG-0 from 18% to 82% (P < .0001), compared with 22%-53% in the WHO-MDT group (P = .0006). RIMOXCLAMIN reduced PDG-2 by 67% at month 6 (P = .002) and 83% at discharge (P < .0001), whereas WHO-MDT showed no change at month 6 and a 50% reduction at discharge. At month 3, neurological symptoms were greater in the RIMOXCLAMIN group than in the WHO-MDT, with no intragroup differences. WHO-MDT showed higher adverse events, including severe anemia (requiring dapsone discontinuation in 33.9% [20/59]). RIMOXCLAMIN adverse events were mild, requiring regimen adjustments in 19.4% (20/103) without additional medications. A general limitation is…
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.